The Access to Prescription Digital Therapeutics Act of 2023 will help ensure that the greatest number of patients possible are receiving innovative, modern care, which is especially vital for closing care gaps caused by specialist shortages or geographic obstacles. View the issue brief to learn more.
Spinal Muscular Atrophy Resources
Spinal muscular atrophy (SMA) is a rare, autosomal recessive genetic disease that causes progressive muscle weakness and atrophy. Approximately 6,000 children and adults in the United States are affected, making SMA one of the most common rare diseases. AMCP conducted a virtual Market Insights program to identify perspectives of AMCP members on current and future therapies for SMA.
AMCP Market Insights Summit: Spinal Muscular Atrophy (SMA)
-
Proceedings:
Findings from the AMCP Market Insights Program
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.